Clinical Issues in Rheumatoid ArthritisDebates & Discussions on the Evolving Role of JAK Inhibitors
This activity is provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Gilead Sciences, Inc.
This is not an official program of the American College of Rheumatology.
Dinner will be provided.
The educational design of this activity addresses the needs of clinical rheumatologists and specialist NPs, PAs, and nurses who manage patients with rheumatoid arthritis (RA).
Statement of Need/Program Overview
Advances in our understanding of the immunopathologic mechanisms underlying (RA) have led to the development of disease-modifying antirheumatic drugs (DMARDs) that effectively target relevant pathways. For instance, members of the Janus kinase (JAK) family play a pivotal role in transducing extracellular cytokine signaling, thereby contributing to such processes as cellular proliferation, homeostasis, and host defense against infections.1 In RA, certain JAK-mediated signaling pathways are dysfunctionally active, leading to enhanced transcription of various proinflammatory genes and aberrant immune responses.2 In this Clinical Issues™ program, a panel of expert rheumatologists will discuss and debate the latest insights into JAK activation in RA immunopathology, recent clinical trial data on the efficacy and safety of current and emerging JAK inhibitors, and the evolving roles of this DMARD class in day-to-day practice. The overall goal is to prepare attendees to translate the latest information on JAK inhibitors into better care for their patients with RA.
- Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-243.
- Malemud C. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(5-6):117-127.
Upon completion of this activity, participants will be better able to:
- Describe the roles of JAK/STAT signaling in immune responses and homeostasis, including contributions to the immunopathogenesis of RA
- Discuss the clinical profiles of current and emerging JAK inhibitors, including implications of enzyme specificity and evidence for efficacy and safety in RA
- Integrate JAK inhibitors into RA-treatment algorithms based on guideline recommendations, current clinical trial data, and patient preferences
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
5:30 PM - 6:00 PM - Registration and Dinner
6:00 PM - 6:10 PM - Introductions and Preactivity Questionnaire
6:10 PM - 6:30 PM - RA Pathophysiology: The Mechanistic Rationale for JAK Inhibition
6:30 PM - 6:55 PM - Current and Emerging JAK Inhibitors: What is the Evidence in RA?
6:55 PM - 7:15 PM - Integrating JAK Inhibitors into RA Treatment Algorithms
7:15 PM - 7:30 PM - Postactivity Questionnaire and Question & Answer Session
There is no registration fee for attending this program, however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.
Americans With Disability Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at email@example.com.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.